University of Newcastle
Callaghan, New South Wales, Australia
Evangeline Jackson is a PhD candidate at the University of Newcastle, Hunter Medical Research Institute, Australia. Miss Jackson joined the Cancer Signalling Research Group (CSRG), led by Professor Matthew Dun in 2018, being awarded with a Bachelor of Biomedical Science (Honours 1) in 2019, following a research project in Diffuse Midline Glioma (DMG).
Miss Jackson began her PhD candidature in May 2020, focused on the novel therapeutic, ONC201 for the treatment of DMG. She employs sophisticated methods in proteomics and molecular biochemistry, to inform mechanistic studies aimed at improving treatment response through combination treatment paradigms. Using systems-wide approaches, harnessing a greater understanding of DMG biology, she uses patient derived in vitro and in vivo models to investigate clinically relevant therapies for the treatment of DMG. Her preclinical work combining ONC201 with the PI3K/Akt inhibitor, paxalisib, recently published in Cancer Research, has assisted in the development of PNOC-022, an international clinical trial testing ONC201 and paxalisib in combination with standard of care radiotherapy, for patients diagnosed with DMG around the world.
